top of page

Alessandro Di Minno

36-Alessandro Di Minno.png

Name: Alessandro Di Minno, Pharm. D                                

Institution: Dipartimento di Farmacia, Università degli Studi di Napoli Federico II, Naples.

Position Title: Assistant Professor

 

 

Career: In October 2014, Alessandro Di Minno graduated in Pharmacy (110/110) at Federico II University, Naples with an experimental thesis on the role of cAMP and cGMP in the regulation of gas-transmitters with emphasis on hydrogen sulphide (H2S). In the frame of his PhD program in Experimental and Clinical Pharmacological Sciences in Milan University (November 2014- November 2017), he joined the Unit of Metabolomics and Cellular Biochemistry of Atherothrombosis at Centro Cardiologico Monzino IRCCS in Milan. There, he actively worked on targeted and untargeted metabolomics and on oxidative stress markers and the Arg/NO metabolome. After his PhD graduation (January 2018), he joined the Unit of Metabolomics and Cellular Biochemistry of Atherothrombosis at Centro Cardiologico Monzino Milan, Italy as Research Associate (3-yr position). In December 2018 he got a 3-yr position as Assistant Professor of Technical Sciences of Laboratory Medicine at the Department of Pharmacy, Federico II University, Naples. He is a member of the faculty of the Master entitled “Nutraceutical products: from research and development to marketing”. On November 2018 he won the XXIII International Award “Nunzio e Adriana Pascale”. On November 2019 he won the best poster at 51°National Congress SIBIOC-Laboratory Medicine

 

Research carried out. Following graduation in Pharmacy, his research interest has been focused on targeted metabolomics. Using validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods, he has been involved in several lines of research. He has personally and actively carried out the following: in vivo measurements of 8-oxo-7,8-dihydro-2'-deoxyguanosine (a biomarker of DNA damage); in vivo and ex vivo measurements of platelet activation -as reflected by the urinary excretion of 11-dehydro-TxB2 (11-DH TxB2) and by the ex vivo measurement of TxB2-; enhanced urinary excretion of 8-iso-prostaglandinF2α (8-iso-PGF2α), a reliable in vivo marker of lipid peroxidation; downregulation of monocyte-derived macrophage efferocytosis by 12(S)-hydroxyeicosatetraenoic acid; indices of activation of Nrf2/Ho-1 pathway and human atherosclerotic plaque vulnerability; characterization of aspirin esterase and of Trimethylamine N-Oxide (TMAO) activity. He has been also actively involved in plasma lipid composition in patients with homocystinuria due to cystathionine-β-synthase deficiency (untargeted lipidomics), and in the relationships between phospholipid changes and in vivo platelet activation in this setting. All the methods alluded to in the present research proposal have been validated and/or developed by the researcher himself together with the components of the Unit of Metabolomics and Cellular Biochemistry of Atherothrombosis and the Centro Cardiologico Monzino, IRCCS and have been described in published (or in preparation) papers. He authorized more than 90 publications in international journals with an H-index of 21. He is, also an Editorial Board member for major journals such as Blood Reviews, Journal of Clinical Medicine and International Journal of Molecular Sciences. He served also as reviewer for major journals such as Clinical Nutrition, European Journal of Clinical Pharmacology, International Journal of Cardiology, Thrombosis and Haemostasis, British Journal of Clinical Pharmacology, Journal of Cardiovascular Pharmacology and Therapeutics and Biochemical Pharmacology.

bottom of page